drugset / Trial / NCT00485407

Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine

NCT00485407

Phase 3 Completed 377 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine

Timeline

Start
2003-07
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified